Home  |  Contact

UniProtKB/Swiss-Prot Q9BT22: Variant p.Leu366Gln

Chitobiosyldiphosphodolichol beta-mannosyltransferase
Gene: ALG1
Variant information

Variant position:  366
The position of the amino-acid change on the UniProtKB canonical protein sequence.

Type of variant:  LP/P [Disclaimer]
The variants are classified into three categories: LP/P, LB/B and US.
  • LP/P: likely pathogenic or pathogenic.
  • LB/B: likely benign or benign.
  • US: uncertain significance

Residue change:  From Leucine (L) to Glutamine (Q) at position 366 (L366Q, p.Leu366Gln).
Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.

Physico-chemical properties:  Change from medium size and hydrophobic (L) to medium size and polar (Q)
The physico-chemical property of the reference and variant residues and the change implicated.

BLOSUM score:  -2
The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another:
  • Lowest score: -4 (low probability of substitution).
  • Highest score: 11 (high probability of substitution).
More information can be found on the following page

Variant description:  In CDG1K; decreased function in protein glycosylation as shown by rescue assays in an ALG1-deficient yeast strain.
Any additional useful information about the variant.

Other resources:  
Links to websites of interest for the variant.



Sequence information

Variant position:  366
The position of the amino-acid change on the UniProtKB canonical protein sequence.

Protein sequence length:  464
The length of the canonical sequence.

Location on the sequence:   PWLEAEDYPLLLGSADLGVC  L HTSSSGLDLPMKVVDMFGCC
The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.

Residue conservation: 
The multiple alignment of the region surrounding the variant against various orthologous sequences.

Human                         PWLEAEDYPLLLGSADLGVCLHTSSSGLDLPMKVVDMFGCC

Mouse                         PWLEAEDYPLLLGSADLGVCLHMSSSGLDLPMKVVDMFGCH

Slime mold                    VWLDSEDYPKLLACCDLGVSLHNSSSGIDLPMKVVDMFGCC

Baker's yeast                 VWLSAEDYPKLLQLCDYGVSLHTSSSGLDLPMKILDMFGSG

Fission yeast                 PWLSIEDYPQVMACADLGVCLHTSSSGLDLPMKVVDLFGCG

Sequence annotation in neighborhood:  
The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:
  • Type: the type of sequence feature.
  • Positions: endpoints of the sequence feature.
  • Description: contains additional information about the feature.

TypePositionsDescription
Chain 1 – 464 Chitobiosyldiphosphodolichol beta-mannosyltransferase
Topological domain 24 – 464 Lumenal


Literature citations

ALG1-CDG: Clinical and Molecular Characterization of 39 Unreported Patients.
Ng B.G.; Shiryaev S.A.; Rymen D.; Eklund E.A.; Raymond K.; Kircher M.; Abdenur J.E.; Alehan F.; Midro A.T.; Bamshad M.J.; Barone R.; Berry G.T.; Brumbaugh J.E.; Buckingham K.J.; Clarkson K.; Cole F.S.; O'Connor S.; Cooper G.M.; Van Coster R.; Demmer L.A.; Diogo L.; Fay A.J.; Ficicioglu C.; Fiumara A.; Gahl W.A.; Ganetzky R.; Goel H.; Harshman L.A.; He M.; Jaeken J.; James P.M.; Katz D.; Keldermans L.; Kibaek M.; Kornberg A.J.; Lachlan K.; Lam C.; Yaplito-Lee J.; Nickerson D.A.; Peters H.L.; Race V.; Regal L.; Rush J.S.; Rutledge S.L.; Shendure J.; Souche E.; Sparks S.E.; Trapane P.; Sanchez-Valle A.; Vilain E.; Voello A.; Waechter C.J.; Wang R.Y.; Wolfe L.A.; Wong D.A.; Wood T.; Yang A.C.; Matthijs G.; Freeze H.H.;
Hum. Mutat. 37:653-660(2016)
Cited for: INVOLVEMENT IN CDG1K; FUNCTION; VARIANTS CDG1K ARG-50; PHE-71; LEU-74; VAL-88; LEU-98; PHE-114; ARG-150; SER-209; LEU-258; TRP-276; PHE-281; GLY-289; VAL-291; ASP-353; ARG-358; LEU-359; VAL-360; ALA-363; GLN-366; GLN-367; LYS-382; ARG-384; SER-388 AND TRP-438; CHARACTERIZATION OF VARIANTS CDG1K ARG-50; PHE-71; LEU-74; VAL-88; LEU-98; PHE-114; ARG-150; SER-209; LEU-258; TRP-276; PHE-281; GLY-289; VAL-291; ASP-353; ARG-358; LEU-359; VAL-360; ALA-363; GLN-366; GLN-367; LYS-382; ARG-384; SER-388 AND TRP-438; CHARACTERIZATION OF VARIANT ASN-267;

Disclaimer: Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.